FDA Approves Sub-q Tx for PNH – Empaveli
Last week the FDA approved a new sub-q therapy, Empaveli (pegcetacoplan) from Apellis Pharmaceuticals, for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who
May 25, 2021
Last week the FDA approved a new sub-q therapy, Empaveli (pegcetacoplan) from Apellis Pharmaceuticals, for the treatment of adults with paroxysmal nocturnal hemoglobinuria (PNH) who
We are always on the lookout for updates on health systems that own or operate their own specialty pharmacies as well as third-party organizations that
Today we now better understand how UBER costly drugs, such as the big-ticket CAR-T therapies, are billed and paid for in our highly fractional health
Over the years I’ve been able to visit dozens of specialty pharmacies working with pharmacy leadership to help develop new programs. Each of these new
How time flies!About three years ago Amazon jumped into the prescription business throwing a new monkey wrench in the segment. So, what’s happened in that
Were there fireworks to mark the event?Was there a parade to commemorate the long-awaited day?In short, NO! Annual Drug Trend Reports from Express Scripts (Evernorth)
The FDA approved a new infused specialty therapy last week, Zynlonta (loncastuximab tesirine-lpyl) from ADC Therapeutics, for the treatment of adult patients with relapsed or
We’ve ranted about the encroachment of hospital and health system owned specialty pharmacies more times that one can count. The growth of these organizations seemed
Last week the FDA approved a new specialty therapy, Jemperli (dostarlimab) from GlaxoSmithKline, for treating patients with recurrent or advanced endometrial cancer. Uterine cancers are
The article below details a new PSAO option for pharmacies, the ‘first’ PSAO for community-based specialty pharmacies from AmerisourceBergen named the Accelerate Specialty Network. Network
